Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK (TheStreet) -- Regeneron Pharmaceuticals (Nasdaq:REGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of B . The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

• EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Highlights from the ratings report include:

• REGN's very impressive revenue growth greatly exceeded the industry average of 7.9%. Since the same quarter one year prior, revenues leaped by 315.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
• The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. When compared to other companies in the Biotechnology industry and the overall market, REGENERON PHARMACEUT's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
• 49.50% is the gross profit margin for REGENERON PHARMACEUT which we consider to be strong. It has increased significantly from the same period last year. Along with this, the net profit margin of 44.80% significantly outperformed against the industry average.
• Net operating cash flow has significantly increased by 94.90% to -$2.38 million when compared to the same quarter last year. In addition, REGENERON PHARMACEUT has also vastly surpassed the industry average cash flow growth rate of -67.24%.
• The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 407.0% when compared to the same quarter one year prior, rising from -$62.37 million to $191.47 million.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron has a market cap of $13.83 billion and is part of the health care sector and drugs industry. The company has a P/E ratio of 74.3, above the S&P 500 P/E ratio of 17.7. Shares are up 164.1% year to date as of the close of trading on Friday.

You can view the full Regeneron Ratings Report or get investment ideas from our investment research center.

--Written by a member of TheStreet Ratings Staff.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!

For more information on Regeneron Pharmaceuticals Inc. click any of the following:

• Regeneron Pharmaceuticals Inc. Stock Price

• Regeneron Pharmaceuticals Inc. Analyst Ratings

• Regeneron Pharmaceuticals Inc. Key Stats & Profile

• Regeneron Pharmaceuticals Inc. Earnings

• Regeneron Pharmaceuticals Inc. Ratio Comparison

• Regeneron Pharmaceuticals Inc. Growth Rates

• Regeneron Pharmaceuticals Inc. Balance Sheet

• Regeneron Pharmaceuticals Inc. Cash Flow

• Regeneron Pharmaceuticals Inc. Income Statement